One small pharma company is meeting the challenge of COVID-19 by finding new ways to support the practices of its specialist physician customers.

The U.S. Food and Drug Administration approved Allergan’s Durysta (bimatoprost implant) 10 mcg for intracameral administration to treat open-angle glaucoma (OAG) or ocular hypertension.

High cholesterol is associated with an increased risk of developing glaucoma, but a new study suggests taking statins to lower cholesterol helps to reduce this risk.

The U.S. FDA approved the New Drug Application of Xelpros 0.005% for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Meeting physical activity guidelines and being physically fit may reduce the risk of developing glaucoma by 40 percent to 50 percent, recent research suggests.

People who drink hot tea daily may be less likely than others to develop glaucoma symptoms, U.S. researchers say.

Mallinckrodt plc will acquire Sucampo Pharmaceuticals Inc., including its commercial and development assets.

Canadian drugmaker Valeant Pharmaceuticals International Inc. said the U.S. Food and Drug Administration approved Lumify drop to treat eye redness.

The FDA approved Aerie Pharmaceuticals Inc.’s eyedrop Rhopressa as a treatment for glaucoma, two months ahead of the expected date.

A large group of U.S. states accused key players in the generic drug industry of a broad price-fixing conspiracy, moving to widen an earlier lawsuit to add many more drugmakers and medicines in an action that sent some company shares tumbling.